News
Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.
Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...
The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.
Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease ...
Hemostasis Market Insight, Epidemiology and Market Forecast - 2032The hemostasis market is experiencing significant expansion, driven by inc ...
Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...
This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...
5d
MedPage Today on MSNStem Cell Therapy Begins to Emerge as Potential IBD TreatmentThere's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape, a process that can go haywire or fail to work. But what if the body could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results